Akari Therapeutics To Present Abstract On Potential Once Weekly PAS-Coversin At The 58th Annual Meeting Of The American Society Of Hematology

NEW YORK and LONDON, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that an abstract has been accepted at the 58th Annual Meeting of the American Society of Hematology in San Diego, CA, from December 3-6, 2016.  Abstract publication number 5900 entitled, "Therapeutic Development of Complement C5 inhibitor Coversin TM with Extended Half-life via PASylation®," details the modifications made to extend the half-life of Coversin from a self-administered once-daily subcutaneous injection to potential weekly dosing for enhanced patient convenience.  The abstract authors are Miles Nunn, Chief Scientific Officer of Akari Therapeutics and Arne Skerra, Chairman & Founder of XL-protein GmbH.   The abstract also provides an update on the first PNH patient on unmodified Coversin therapy who is eculizumab resistant.  This patient has now been treated for more than 8 months and continues to respond well to treatment.

PASylation® entails modifying Coversin, a recombinant small protein (17kDa), by adding a 600 amino acid proline/alanine/ serine (PAS) N-terminal fusion tag to generate PAS-Coversin (68kDa). The unstructured and uncharged PAS polypeptide increases the apparent molecular size to approximately 720kDa, slowing kidney clearance and extending the half-life.  In mouse models, subcutaneously delivered PAS-Coversin was 100% bioavailable with a 52-fold increase in half-life compared to unmodified Coversin.  In vitro complement lytic and C5 binding assays indicate PAS-Coversin inhibits complement C5 as potently as unmodified Coversin.

Abstracts for the conference are available online at  http://www.hematology.org/Annual-Meeting/.

Additionally, Akari will host an Analyst & Investor Symposium on Saturday, December 3, 2016 at 6:30pm PT at the Hotel Indigo in San Diego.  The company will provide an update on its development pipeline.  Reprints of the oral presentation and symposium slides will all be made available for download from the Company's website,  http://www.akaritx.com following the presentations at ASH.

About Akari Therapeutics Plc

Akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. Akari's lead drug, Coversin is a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b-9 (also known as the membrane attack complex or MAC). C5 inhibition is growing in importance in a range of rare autoimmune diseases related to dysregulation of the complement component of the immune system, including Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), and Guillain Barré syndrome (GBS).

If you liked this article you might like

Biotech Movers: Akari, Array, Amicus

Traders Are Focused on the Big-Caps